


| | | |
|---|--|---|
| FORM PTO - 1449 THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | | ATTORNEY DOCKET NO.: LEX-007 APPLICANT(S): Gillies <i>et al.</i> SERIAL NO.: 09/621,268 FILING DATE: July 21, 2000 GROUP: 1642 |
|---|--|---|



| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|-----|--------------------|----------|--------------------------|-------|--------------|-------------------------------|
| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
| KAC | A75 | 4,703,008 | 10/27/87 | Lin | | | |
| | A76 | 5,441,868 | 8/15/95 | Lin | | | |
| | A77 | 5,457,038 | 10/10/95 | Trinchieri <i>et al.</i> | | | |
| | A78 | 5,547,933 | 8/20/96 | Lin | | | |
| | A79 | 5,618,698 | 4/8/97 | Lin | | | |
| | A80 | 5,688,679 | 11/18/97 | Powell | | | |
| | A81 | 5,756,349 | 5/26/98 | Lin | | | |
| | A82 | 5,955,422 | 9/21/99 | Lin | | | |
| | A83 | 6,231,536 | 5/15/01 | Lentz | | | |
| | A84 | 6,284,536 | 9/4/01 | Morrison <i>et al.</i> | | | |
| | A85 | 6,340,742 | 1/22/02 | Burg <i>et al.</i> | | | |
| | A86 | 6,506,405 | 1/14/03 | Desai <i>et al.</i> | | | |
| | A87 | 6,583,272 | 6/24/03 | Bailon | | | |
| | A88 | 6,586,398 | 7/1/03 | Kinstler <i>et al.</i> | | | |
| | A89 | 2002/0142374 | 10/3/02 | Gallo <i>et al.</i> | | | |
| | A90 | 2003/0003529 | 1/2/03 | Bayer | | | |
| ✓ | A91 | 2003/0012789 | 1/6/03 | Blumberg <i>et al.</i> | | | |

FOREIGN PATENT DOCUMENTS

| EXAM INIT. | | DOCUMENT NUMBER | DATE | COUNTRY CODE | CLASS | SUB CLASS | FILING DATE | ABSTRACT ONLY | ENGLISH LANG (Y/N) |
|---------------|------|--------------------|--------|-----------------|-------|--------------|----------------|------------------|--------------------------|
| KAC | B105 | WO 00/24893 | 5/4/00 | PCT | | | | | |

EXAM. INIT. OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)

| | | |
|-----|------|--|
| KAC | C180 | Becker <i>et al.</i> , (1996), "Long-lived and Transferable Tumor Immunity in Mice after Targeted Interleukin-2 Therapy," <i>J Clin Invest.</i> , 98(12):2801-2804. |
| | C181 | Becker <i>et al.</i> , (1996), "T Cell-mediated Eradication of Murine Metastatic Melanoma Induced by Targeted Interleukin-2 Therapy," <i>J Exp. Med.</i> , 183(50):2361-6. |
| ✓ | C182 | Briggs <i>et al.</i> , (1974), "Hepatic Clearance of Intact and desialylated Erythropoietin," <i>American Journal of Physiology</i> , 227(6):1385-1388. |

EXAMINER *[Signature]* DATE CONSIDERED 11/29/05

| FORM PTO - 1449 | | ATTORNEY DOCKET NO.: LEX-007 | | | | | |
|--|------|---|------|------|-------|--------------|-------------------------------|
| THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies <i>et al.</i> | | | | | |
| | | SERIAL NO.: 09/621,268 | | | | | |
| | | FILING DATE: July 21, 2000 GROUP: 1642 | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
| KAC | C183 | Chuang et al., (1994), "Alteration of Lymphocyte Microtubule Assembly, Cytotoxicity, and Activation by the Anticancer Drug Taxol," <u>Cancer Research</u> , 54:1286-1291. | | | | | |
| | C184 | Cruse et al., (1995), <u>Illustrated Dictionary of Immunology</u> , CRC Press, NY, p.156-7. | | | | | |
| | C185 | Davis et al., (2003), "Immunocytokines: Amplification of Anti-cancer Immunity," <u>Cancer Immunol. Immunother.</u> , 52:297-308. | | | | | |
| | C186 | Dolman et al., (1998), "Suppression of Human Prostate Carcinoma Metastases in Severe Combined Immunodeficient Mice by Interleukin 2 Immunocytokine Therapy," <u>Clin Cancer Res.</u> , 4(10):2551-7. | | | | | |
| | C187 | Duncan et al., (1988), "The Binding Site for Clq on IgG," <u>Nature</u> , 332:738-740. | | | | | |
| | C188 | Egrie et al., (2001), "Development and Characterization of Novel Erythropoiesis Stimulating Protein (NESP)," <u>Nephrol. Dial. Transplant.</u> , 16:3-13. | | | | | |
| | C189 | Elliott et al., (1997), "Mapping of the Active Site of Recombinant Human Erythropoietin," <u>Blood</u> , 89(2):493-502. | | | | | |
| | C190 | Frost et al., (1997), "A Phase I/II Trial of Murine Monoclonal Anti GD2 Antibody 14.G2a Plus Interleukin-2 in Children with Refractory Neuroblastoma," <u>Cancer</u> , 80:317-33. | | | | | |
| | C191 | Gan et al., (1999), "Specific enzyme-linked Immunosorbent Assays for Quantitation of Antibody-cytokine Fusion Proteins," <u>Clin. Diagn. Lab. Immunol.</u> , 6(2):236-42. | | | | | |
| | C192 | Gillies et al., (1991), "Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-ganglioside GD2 Antibody," <u>Hybridoma</u> , 10(3):347-56. | | | | | |
| | C193 | Gillies et al., (2002), "Bi-functional Cytokine Fusion Proteins for Gene Therapy and Antibody-targeted Treatment of Cancer," <u>Cancer Immunol. Immunother.</u> , 51(8):449-60. | | | | | |
| | C194 | Gillies et al., (2002), "Improved Circulating Half-life and Efficacy of an Antibody-interleukin 2 Immunocytokine Based on Reduced Intracellular Proteolysis," <u>Clin. Cancer Res.</u> , 8(1):210-6. | | | | | |
| | C195 | Greene et al., (1975), Neuronal Properties of Hybrid Neuroblastoma X Sympathetic Ganglion Cells," <u>Proc. Natl. Acad. Sci. USA</u> , 72(12):4923-4927. | | | | | |
| | C196 | Hank et al., (1996), "Activation of Human Effector Cells by a Tumor Reactive Recombinant Anti-ganglioside GD2 Interleukin-2 Fusion Protein (ch14.18-IL2)," <u>Clin Cancer Res.</u> , 2(12):1951-9. | | | | | |
| | C197 | Hank et al., (2003), "Determination of peak serum levels and immune response to the humanized anti-ganglioside antibody-interleukin-2-immunocytokine," <u>Methods Mol. Med.</u> , 85:123-31. | | | | | |
| | C198 | Haraguchi, (1994), "Isolation of GD3 Synthase Gene by Expression Cloning of GM3 α -2,8-sialyltransferase cDNA using anti-GD2 Monoclonal Antibody," <u>Proc. Natl. Acad. Sci. USA</u> , 91(22):10455-9. | | | | | |
| | C199 | Harris, (1995), "Processing of C-terminal Lysine and Arginine Residues of Proteins Isolated from Mammalian Cell Culture," <u>J. Chromatogr. A</u> , 705:129-134. | | | | | |
| ✓ | C200 | Hezareh et al, (2001), "Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1," <u>J. Virol.</u> , 75(24):12161-8. | | | | | |
| EXAMINER <i>John P. Gillies</i> | | DATE CONSIDERED <i>11/29/05</i> | | | | | |

| FORM PTO - 1449 THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | | ATTORNEY DOCKET NO.: LEX-007 APPLICANT(S): Gillies <i>et al.</i> SERIAL NO.: 09/621,268 FILING DATE: July 21, 2000 GROUP: 1642 | | | | | |
|---|------|---|------|------|-------|--------------|-------------------------------|
| SEARCHED DOCUMENTS | | | | | | | |
| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
| KAC | C201 | Idusogic et al., (2000), "Mapping of the Clq Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc," <u>J. Immunol.</u> , 164(8):4178-4184. | | | | | |
| | C202 | Imboden et al., (2001), "The Level of MHC Class I Expression on Murine Adenocarcinoma Can Change the Antitumor Effector Mechanism of Immunocytokine Therapy," <u>Cancer Res.</u> , 61(4):1500-7. | | | | | |
| | C203 | Kato et al., (1997), "Mechanism for the Nonlinear Pharmacokinetics of Erythropoietin in Rats," <u>The Journal of Pharmacology and Experimental Therapeutics</u> , 283:520-527. | | | | | |
| | C204 | Kato et al., (1998), "Pharmacokinetics of Erythropoietin in Genetically Anemic Mice," <u>Drug Metabolism and Disposition</u> , 26:126-131. | | | | | |
| | C205 | Kushner et al., (2001), "Phase II Trial of the Anti-GD2 Monoclonal-macrophage-colony-stimulating Factor for Neuroblastoma," <u>J. Clin. Oncol.</u> , 19:4189-94. | | | | | |
| | C206 | Lode et al., (1997), "Targeted interleukin-2 Therapy for Spontaneous Neuroblastoma Metastases to Bone Marrow," <u>J Natl Cancer Inst.</u> , 89(21):1586-94. | | | | | |
| | C207 | Lode et al., (2000), "What to do with Targeted IL-2," <u>Drugs Today</u> , 36(5):321-36. | | | | | |
| | C208 | Lode et al., (2000), "Melanoma Immunotherapy by Targeted IL-2 Depends on CD4(+) T-cell Help Mediated by CD40/CD40L Interaction," <u>J. Clin. Invest.</u> , 105(11):1623-30. | | | | | |
| | C209 | Macdougall, (2002), "Optimizing the Use of Erythropoietic Agents—Pharmacokinetic and Pharmacodynamic Considerations," <u>Nephrol. Dial. Transplant</u> , 17:66-70. | | | | | |
| | C210 | Metelitsa et al., (2002), "Antidisialoganglioside/granulocyte Macrophage-colony-stimulating Factor Fusion Protein Facilitates Neutrophil Antibody-dependent Cellular Cytotoxicity and Depends on FcyRII (CD32)-and Mac-1 (CD11b/CD18) for Enhanced Effector Cell Adhesion and Azurophil Granule Exocytosis," <u>Blood</u> , 99(11):4166-73. | | | | | |
| | C211 | Mueller et al. (1997), "Humanized Porcine VCAM-specific Monoclonal Antibodies with Chimeric IgG2/G4 Constant Regions Block Human Leukocyte Binding to Porcine Endothelial Cells," <u>Molecular Immunology</u> , 34(6):441-452. | | | | | |
| | C212 | Mullins et al. (1997), "Taxol-mediated Changes in Fibrosarcoma-induced Immune Cell Function: Modulation of Antitumor Activities," <u>Cancer Immunol. Immunother.</u> , 45:20-28. | | | | | |
| | C213 | Naramura et al., "Mechanisms of Cellular Cytotoxicity Mediated by a Recombinant Antibody-IL2 Fusion Protein against Human Melanoma Cells," <u>Immunology Letters</u> , 39(1):91-9. | | | | | |
| | C214 | Neal et al. (2003), "NXS2 Murine Neuroblastomas Express Increased Levels of MHC Class I Antigens upon Recurrence Following NK-dependent Immunotherapy," <u>Cancer Immunol. Immunother.</u> , 53:41-52. | | | | | |
| | C215 | Ngo et al., (1994), "The Protein Folding Problem and Tertiary Structure Prediction," pp. 433-440 and 492-495, Birkhauser Boston. | | | | | |
| ✓ | C216 | Niethammer et al., (2002) "An oral DNA Vaccine against Human Carcinoembryonic Antigen (CEA) Prevents Growth and Dissemination of Lewis Lung Carcinoma in CEA Transgenic Mice," <u>Vaccine</u> , 20:421-9. | | | | | |
| EXAMINER <i>John J. Henelle</i> | | DATE CONSIDERED <i>11/29/05</i> | | | | | |

FORM PTO - 1449

ATTORNEY DOCKET NO.: LEX-007

THIRD SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

MAR 09 2004

APPLICANT(S): Gillies *et al.*


SERIAL NO.: 09/621,268

FILING DATE: July 21, 2000 GROUP: 1642

U.S. PATENT DOCUMENTS

| EXAM. INIT. | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
|----------------|------------------------|------|---|-----------------|--------------|-------------------------------|
| KAC | C217 | | Niethammer et al., (2001) "Targeted Interleukin 2 Therapy Enhances Protective Immunity Induced by an Autologous Oral DNA Vaccine against Murine Melanoma," <u>Cancer Research</u> , 61(16):6178-84. | | | |
| | C218 | | Nimtz et al., (1993) Structures of Sialylated Oligosaccharides of Human Erythropoietin Expressed in Recombinant BHK-21 Cells," <u>Eur. J. Biochem.</u> , 213:39-56. | | | |
| | C219 | | Panck et al., (1996), "Eradication of Established Hepatic Human Neuroblastoma Metastases in Mice with Severe Combined Immunodeficiency by Antibody-targeted Interleukin-2," <u>Cancer Immunol. Immunother.</u> , 42(2):88-92. | | | |
| | C220 | | Park et al., (2000), "Efficiency of Promoter and Cell line in High-level Expression of Erythropoietin," <u>Biootechnol. Appl. Biochem.</u> , 32:167-172. | | | |
| | C221 | | Reisfeld et al., (1996), "Antibody-interleukin 2 Fusion Proteins: A New Approach to Cancer Therapy," <u>J Clin Lab Anal.</u> , 10(3):160-6. | | | |
| | C222 | | Reisfeld et al., (1996), "Involvement of B Lymphocytes in the Growth Inhibition of Human Pulmonary Melanoma Metastases in Athymic nu/nu Mice by an Antibody-lymphotoxin Fusion Protein," <u>Cancer Res.</u> , 56(8):1707-12. | | | |
| | C223 | | Ruehlmann et al., (2001), "MIG (C1XCL9) Chemokine Gene Therapy Combines with Antibody-cytokine Fusion Protein to Suppress Growth and Dissemination of Murine Colon Carcinoma," <u>Cancer Res.</u> , 61(23):8498-503. | | | |
| | C224 | | Sabzevari et al., (1994), "A Recombinant Antibody-interleukin 2 Fusion Protein Suppresses Growth of Hepatic Human Severe Combined Immunodeficiency Mice," <u>Proc. Natl. Acad. Sci. USA</u> , 91(20):9626-30. | | | |
| | C225 | | Seidenfeld et al., (2001), "Epoietin Treatment of Anemia Associated with Cancer Therapy: A Systematic Review and Meta-analysis of controlled Clinical Trials," <u>Journal of National Cancer Institute</u> , 93:1204-1214. | | | |
| | C226 | | Shinkawa et al., (2003), "The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity," <u>J. Biol. Chem.</u> , 278:3466-3473. | | | |
| | C227 | | Strom et al., (1996), "Therapeutic Approach to Organ Transplantation," <u>Therapeutic Immunology</u> , Blackwell Science, Chapter 36, pp. 451-456. | | | |
| | C228 | | Thommesen et al., (2000), "Lysine 322 in the Human IgG3 CH2 Domain is Crucial for Antibody Dependent Complement Activation," <u>Mol. Immunol.</u> , 37(16):995-1004. | | | |
| | C229 | | Wells, (1990), "Additivity of Mutational Effect in Proteins," <u>Biochemistry</u> , 29(37):8509-8517. | | | |
| | C230 | | Xiang et al., (1998), "Induction of Persistent Tumor-protective Immunity in Mice Cured of Established Colon Carcinoma Metastases," <u>Cancer Research</u> , 58(17):3918-3925. | | | |
| | C231 | | Xiang et al., (1999) "T Cell Memory against Colon Carcinoma is Long-lived in the Absence of Antigen," <u>J. Immunol.</u> , 163(7):3676-83. | | | |
| ✓ | C232 | | Xiang et al., (2001), "A Dual Function DNA Vaccine Encoding Carcinoembryonic Antigen and CD40 Ligand Trimer induces T Cell-mediated Protective Immunity Against Colon Cancer in Carcinoembryonic Antigen-Transgenic Mice," <u>J. Immunol.</u> , 167(8):4560-5. | | | |
| EXAMINER | <i>John R. Camello</i> | | | DATE CONSIDERED | 11/29/05 | |

FORM PTO - 1449

THIRD SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-007

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/621,268

FILING DATE: July 21, 2000 GROUP: 1642

U.S. PATENT DOCUMENTS

| EXAM. INIT. | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
|----------------|--------------------|------|--|-------|--------------|-------------------------------|
| KAC | C233 | | Xiang et al., (2001), "Protective Immunity Against Human Carcinoembryonic Antigen (CEA) Induced by an Oral DNA Vaccine in CEA-transgenic Mice," <u>Clin Cancer Res.</u> , 7(3 Supp):S856-S864. | | | |
| | C234 | | Yu et al., (1998), "Phase I Trial of a Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 in Patients with Refractory Neuroblastoma and Osteosarcoma," <u>J. Clin. Oncol.</u> , 16(6):2169-80. | | | |
| ↓ | C235 | | Zagozdzon et al. (1999), "Potentiation of Antitumor Effect of IL-12 in Combination with Paclitaxel in Murine Melanoma Model In Vivo," <u>International Journal of Molecular Medicine</u> , 4:645-648. | | | |

EXAMINER John J. Hanley

3030550_1

DATE CONSIDERED 11/29/05